PI
-
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
Moreau, P., Hulin, C., Perrot, A., Arnulf, B., Belhadj, K., Benboubker, L., Zweegman, S., Caillon, H. L., Caillot, D., Avet-Loiseau, H., Delforge, M., Dejoie, T., Facon, T., Sonntag, C. C., Fontan, J., Mohty, M., Jie, K-S., Karlin, L., Kuhnowski, F., Lambert, J. R., & 26 others, 1 Aug 2024, In: The Lancet Oncology. 25, 8, p. 1003-1014 12 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma
Korst, C. L. B. M., O'Neill, C., Bruins, W. S. C., Cosovic, M., Twickler, I., Verkleij, C. P. M., le Clerre, D., Themeli, M., Chion-Sotinel, I., Zweegman, S., Galetto, R., Mutis, T. & van de Donk, N. W. C. J., 25 Jul 2024, In: Journal for Immunotherapy of Cancer. 12, 7, e008769.Research output: Contribution to journal › Article › Academic › peer-review
-
T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple Myeloma
Verkleij, C. P. M., O'Neill, C. A., Broekmans, M. E. C., Frerichs, K. A., Bruins, W. S. C., Duetz, C., Kruyswijk, S., Baglio, S. R., Skerget, S., de Oca, R. M., Zweegman, S., Verona, R. I., Mutis, T. & van de Donk, N. W. C. J., 15 Jul 2024, In: Clinical Cancer Research. 30, 14, p. 3006-3022 17 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications